Abstract : Our group previously demonstrated the suppressive effect of glucagon-like peptide-1 GLP-1 on macrophage-driven atherosclerosis in apolipoprotein E-decient apoE / mice. In the present study we investigated the suppressive effect of GLP-1 on the atherogenic phenotype of vascular smooth muscle cells VSMCs in vivo using apoE / mice, and the proliferation and migration of human VSMCs in vitro. A 4-week infusion of GLP-1 in 17-week-old apoE / mice significantly reduced the proliferative VSMC phenotype stained with SMemb. Platelet-derived growth factor PDGF -BB signi cantly stimulated the proliferation of human aortic VSMCs by three fold. Both 0.1 and 1 nmol / l GLP-1 signi cantly suppressed the PDGF-induced VSMC proliferation, and this suppressive effect was significantly abolished by the GLP-1 receptor antagonist exendin 9−39 50 nmol / l . The GLP-1 receptor agonists liraglutide 100 nmol / l and exendin-4 100 nmol / l mimicked GLP-1, signi cantly suppressing PDGF-induced VSMC proliferation. PDGF-BB signi cantly stimulated the migration of human aortic VSMCs by 1.7 -fold, and this effect was signi cantly suppressed by 1 nmol / l GLP-1. These ndings suggest that GLP-1-related treatments may prevent the progression of atherosclerotic lesions by suppressing the proliferation and migration of VSMCs, which are characteristic features of atherosclerosis.
vascular wall and vascular smooth muscle cell VSMC proliferation 8, 9 . Liraglutide stimulates nitric oxide production 10 and attenuates tumor necrosis factor--induced oxidative stress and inflammation, as well as the expression of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and plasminogen activator inhibitor-1 in human umbilical vein endothelial cells 11, 12 . Chronic infusion of GLP-1 suppresses monocyte / macrophage infiltration into the aortic wall and the development of atherosclerotic lesions in apolipoprotein E-deficient apoE / mice, an animal model of spontaneous atherosclerosis 13 . GLP-1 works via GLP-1R to suppress oxidized low-density lipoprotein oxLDL -induced foam cell formation in exudate peritoneal macrophages, and this suppressive effect is followed by activation of cAMP 13 .
In the present study we evaluated the degree to which GLP-1 inhibited the development of aortic atherosclerotic lesions as a result of reducing the area of atherosclerotic lesions infiltrated by proliferative VSMCs in apoE / mice. We assessed the suppressive effects of GLP-1 and GLP-1R agonists on the proliferation and migration of human VSMCs, pivotal features of atherosclerosis.
Materials and methods

Chemicals and reagents
Human GLP-1 7−36 amide, exendin 9−39 , and exendin-4 were purchased from AnaSpec San Jose, CA, USA . Liraglutide was obtained from Bachem Torrance, CA, USA . The dipeptidyl peptidase-4 DPP-4 inhibitor vildagliptin and its analog PKF275-055 were generous gifts of Novartis Basel, Switzerland . Platelet-derived growth factor PDGF -BB was purchased from Wako Osaka, Japan .
Human VSMC proliferation assay
Human aortic VSMCs were seeded on six-well plates 3 10 4 cells / ml per well and cultured in smooth muscle cell basal medium SmBM supplemented with 5 fetal calf serum FCS for 24 h before being transferred to SmBM without FCS to synchronize the cell cycle. VSMCs were incubated for 48 h with PDGF-BB 20 ng / ml and GLP-1, liraglutide, or exendin-4 at concentrations indicated, together with 2 µmol / l PKF-275 to prevent the incretin from degrading. Cells were exposed to 10 µmol / l 5'-bromo-2'-deoxyuridine BrdU for the last 20 h of culture 14 .
BrdU-positive cells were visualized by immunostaining and counted under a microscope.
Human VSMC migration assay
Cell migration was measured using modified Boyden chambers Neuro Probe, Gaithersburg, MD, USA . Each chamber housed a polycarbonate filter with 8-µm pores that had been incubated with 5.3 mg / ml collagen Centrix, Santa Clara, CA, USA in phosphate-buffered saline PBS for 30 min before the migration assay 14 16 . Then, after 4 weeks infusion, systolic blood pressure SBP was measured using indirect tail-cuff equipment MK-2000 ; Muromachi Kikai, Tokyo . Blood samples were collected from the inferior vena cava after mice had been fasted for 12 h. All surgery was performed in mice anesthetized with diethyl ether. Plasma concentrations of glucose were measured by enzymatic methods using an autoanalyzer Hitachi 7020 ; Hitachi, Tokyo, Japan .
Assessment of atherosclerotic lesions
After the 4-week infusion period, the 21-week-old apoE / mice were anesthetized with diethyl ether, drained of blood via the descending vena cava, and subjected to whole-body perfusion with PBS via a left ventricular cannula 13, [16] [17] [18] [19] . The whole aorta was fixed by perfusion with PBS containing 4 paraformaldehyde, excised from the root to the abdominal area, and carefully stripped of connective and adipose tissues. Next, cross-sections of the aortic root were stained with anti-human SM2 antibody Yamasa, Tokyo, Japan and anti-SMemb antibody Yamasa to assess the contractive and proliferative VSMC phenotypes, respectively. VSMCpositive areas are expressed as a percentage of the area of atheromatous plaques.
Statistical analysis
Data are expressed as the mean SEM. Parameters were compared between the two groups by unpaired Student s t-test. The significance of differences was determined using GraphPad Prism 5 GraphPad Software Inc., San Diego, CA, USA . Differences were considered significant at P 0.05.
Results
The body weight of saline-and GLP-1-infused apoE / mice was comparable 30 1 vs 29 1 g, respectively ; P 0.56 , as was systolic blood pressure 99 3 vs 102 3 mmHg, respectively ; P 0.61 , and serum glucose 131 7 vs 141 10 mg / dl, respectively ; P 0.48 .
Effects of GLP-1 on proliferative VSMCs in atherosclerotic lesions in apoE / mice
Similar to results reported previously 13 , apoE / mice infused with saline vehicle in the present study exhibited marked atherosclerotic lesions in the proximal portion of the aorta at 21 weeks of age, whereas 4-week infusion of GLP-1 significantly suppressed the size of the atherosclerotic lesions with infiltrating monocytes / macrophages in the aortic root. Staining of cross-sections of the aortic root with anti-SM2 antibody or anti-SMemb antibody Fig. 1A revealed that GLP-1 infusion significantly decreased SMemb i.e. the proliferative VSMC phenotype by 33.9 compared with staining in the saline-treated group P 0.01; Fig. 1A , C . However, GLP-1 infusion had no significant effect on SM2 staining i.e. the contractile phenotype within aortic atherosclerotic lesions in apoE / mice Fig. 1A , B .
Effects of GLP-1 on the proliferation of human VSMCs
PDGF-BB significantly stimulated the proliferation of human aortic VSMCs by three fold Fig. 2A 
Discussion
The results of the present study suggest that GLP-1 treatments may prevent the progression of atherosclerotic lesions by suppressing the proliferation and migration of VSMCs, which are characteristic features of atherosclerosis. The present study is the first to show the suppressive effects of GLP-1 and GLP-1R agonists on PDGF-BB-induced proliferation and migration of human aortic VSMCs. The present study also showed that GLP-1 suppressed SMemb-positive VSMCs, a proliferative phenotype that acquires macrophage-like phagocytosis 20 . In previous studies we showed that chronic infusion of GLP-1 significantly prevented the infiltration of reported that exendin-4 suppresses murine VSMC proliferation and reduces intimal thickening after vascular injury 9 . These findings are similar to those of the present study and suggest that incretin-based therapy may be effective for the prevention of atherosclerotic vascular diseases. DPP-4 acts on human VSMCs and monocytes / macrophages, and is present in human serum contained in culture medium 22, 23 . In preliminary studies, GLP-1 had far weaker suppressive effects against human macrophage foam cell formation and human VSMC migration and proliferation when the culture media were prepared without DPP-4 inhibitor. Therefore, in the present study, we used DPP-4 inhibitors to prevent degradation of GLP-1 in all ensuing in vitro experiments investigating the suppressive effects of this incretin on human vascular cells.
The concentrations of GLP-1 used in vitro 0.1−1 nmol / l in studies of human VSMC proliferation and migration are higher than concentrations found in vivo in plasma from nonfasted patients with diabetes 2−40 pmol / l 24, 25 . It has been reported that GLP-1 administered via buccal tablets 119 nmol or via continuous infusion 2.16 nmol / kg per day for 2 days increases plasma GLP-1 concentrations in humans to a peak of 100−120 pmol / l 26, 27 . Therefore, the combined use of DPP-4 inhibitors and GLP-1 could conceivably lead to higher plasma concentrations of GLP-1. In humans infused with liraglutide once daily, plasma concentrations have been reported to reach 10 nmol / l liraglutide 28 . Thus, the concentrations of GLP-1 used in the present study do not far exceed the plasma concentrations reached when a GLP-1 analog is administered. The mechanisms underlying the suppressive effects of incretins on the proliferation and migration of VSMCs remain to be elucidated. Goto et al 9 investigated the molecular mechanisms underlying exendin-4-mediated suppression of VSMCs, however their results did not enable them to reach any definitive conclusions. Because GLP-1 has suppressive effects on VSMCs, it is likely that these effects are mediated by cAMP generation following activation of GLP-1R. However, Goto et al 9 did not find increased cAMP levels in exendin-4-treated VSMCs. Hattori et al 10 found that activation of GLP-1R induces phosphorylation of AMPactivated protein kinase AMPK independent of adenylate cyclase activity in endothelial cells. AMPK activation by the GLP-1 signal transduction pathway may be involved in the inhibition of VSMC proliferation. Further studies are required to elucidate the molecular mechanisms underlying the suppression of the proliferation and migration of VSMCs by incretins, and whether these mechanisms are dependent or independent of cAMP. There are several obstacles in translating the findings of the present study to humans. First, unlike humans, in whom the etiology of atherosclerosis is multifactorial, the atherosclerosis in our animal model is due simply to hypercholesterolemia without any other risk factors. Furthermore, in the present study we started the intervention in young 17-week-old mice and evaluated atherosclerotic lesions 4 weeks later. Therefore, this study evaluated the effects of intervention at a young age on the development of atherosclerosis, which differs from the design of intervention studies in humans, in which cardiovascular events or mortality are considered as end-points at older ages.
The Examine SAVOR Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus study in humans failed to demonstrate a suppressive effect of a DPP-4 inhibitor on cardiovascular events 29 . Therefore, other evidence is needed to determine whether incretin-based treatment will really suppress atherosclerosis in humans. Based on the findings of Examin SAVOR, it is difficult at present to extend our findings to suppression of atherosclerosis in humans. However, if it could be demonstrated that incretin-based treatment suppressed atherosclerosis in humans, our results would contribute to an understanding of the mechanisms involved and perhaps the development of appropriate treatment.
In conclusion, the results of the present study indicate that GLP-1 and GLP-1R agonists suppress VSMC migration and proliferation, and are thereby capable of preventing the progression of atherosclerotic lesions. GLP-1-related treatments are expected to emerge as a new line of therapy against atherosclerotic vascular diseases in diabetics.
